ArticleBMC cancer2025
Long noncoding RNA BMPR1B-DT promotes anoikis and reduces proliferation in ovarian cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionOvarian cancer significantly contributes to cancer-related deaths among women. Resistance to anchorage-dependent cell death (anoikis) plays a vital role in facilitating metastasis and worsening patient prognosis. Recent developments in the field of cancer biology have underscored the importance of long noncoding RNAs (lncRNAs) as crucial regulatory entities. However, their functions in the context of anoikis, particularly in ovarian cancer patients, remain inadequately understood. MATERIALS AND
methodsWe conducted a comprehensive analysis of transcriptome data obtained from public databases, with a focus on screening lncRNAs associated with anoikis-related genes. A novel prognostic model that integrates risk scores to evaluate the predictive efficacy for patient outcomes was developed. We subsequently assessed the expression levels and functional role of the lncRNA BMPR1B-DT in ovarian cancer tissues through various techniques, including Western blot analysis, quantitative real-time polymerase chain reaction (qRT‒PCR), cell counting kit-8 (CCK‒8) assays, and flow cytometry.
resultsOur research demonstrates that the anoikis-related lncRNA prognostic model has significant clinical value in predicting the survival outcomes of ovarian cancer patients. Additionally, our study revealed that expression of the lncRNA BMPR1B-DT is upregulated in ovarian cancer tissues and cell lines. Moreover, we revealed that BMPR1B-DT promotes anoikis and inhibits proliferation under suspension culture conditions in ovarian cancer cells.
conclusionOur results suggest that BMPR1B-DT expression is critical in the process of anoikis in ovarian cancer patients. These insights underscore the necessity for further investigations aimed at translating these findings into clinical applications to improve diagnostic and therapeutic approaches for ovarian cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.